Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

699
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
699
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

2.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

2.4K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

909
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
909
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

3.4K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.4K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Where's your head at? Perceptions and utilisation of concussion prevention and rehabilitation strategies in women's and men's rugby union.

Journal of science and medicine in sport·2025
Same author

Prioritising patient and public involvement and engagement in military settings is vital for effective musculoskeletal injury mitigation programmes.

BMJ military health·2024
Same author

Clinical, metabolic, and molecular genetic characterization of hereditary methemoglobinemia caused by cytochrome b<sub>5</sub> reductase deficiency in 30 dogs.

Scientific reports·2020
Same author

A homozygous ADAMTS2 nonsense mutation in a Doberman Pinscher dog with Ehlers Danlos syndrome and extreme skin fragility.

Animal genetics·2019
Same author

The fate of chlorine and organic materials in swimming pools.

Chemosphere·2003
Same author

A randomized controlled trial on the effect of educational interventions in promoting airway management skill maintenance.

Annals of emergency medicine·2000

Related Experiment Video

Updated: Jan 12, 2026

Live Cell Imaging and 3D Analysis of Angiotensin Receptor Type 1a Trafficking in Transfected Human Embryonic Kidney Cells Using Confocal Microscopy
09:51

Live Cell Imaging and 3D Analysis of Angiotensin Receptor Type 1a Trafficking in Transfected Human Embryonic Kidney Cells Using Confocal Microscopy

Published on: March 27, 2017

10.1K

Angiotensin II receptor subtypes and cardiac function

M de Gasparo1, H Rogg, M Brink

  • 1Cardiovascular Research Department, CIBA-GEIGY Limited, Basel, Switzerland.

European Heart Journal
|December 1, 1994
PubMed
Summary

The study found that angiotensin II receptor AT1 density decreases with cardiac dysfunction severity, while AT2 receptor density increases. AT1 receptor antagonists inhibited cardiac hypertrophy in rats.

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.4K
Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

39.0K

Related Experiment Videos

Last Updated: Jan 12, 2026

Live Cell Imaging and 3D Analysis of Angiotensin Receptor Type 1a Trafficking in Transfected Human Embryonic Kidney Cells Using Confocal Microscopy
09:51

Live Cell Imaging and 3D Analysis of Angiotensin Receptor Type 1a Trafficking in Transfected Human Embryonic Kidney Cells Using Confocal Microscopy

Published on: March 27, 2017

10.1K
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.4K
Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

39.0K

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Renal Physiology

Background:

  • The renin-angiotensin system (RAS) plays a crucial role in cardiovascular regulation.
  • Components of the RAS, including angiotensin II receptor subtypes AT1 and AT2, are present in the human heart.
  • Receptor density varies across cardiac chambers, with higher density in the right atrium compared to the left ventricle in normal hearts.

Purpose of the Study:

  • To investigate the role of angiotensin II receptor subtypes AT1 and AT2 in cardiac dysfunction.
  • To examine changes in receptor density in pathological heart conditions.
  • To assess the therapeutic potential of targeting these receptors in cardiac hypertrophy.

Main Methods:

  • Analysis of right atrial membranes from pathological human hearts.
  • Assessment of receptor density in relation to cardiac dysfunction severity.
  • Pharmacological intervention using AT1 receptor antagonists in hypertrophic rats.

Main Results:

  • In pathological hearts, AT1 receptor density decreased, while AT2 receptor density increased with the severity of cardiac dysfunction.
  • Treatment with AT1 receptor antagonists effectively inhibited cardiac hypertrophy in rats.
  • The study demonstrated a reversal of increased receptor density following antagonist treatment.

Conclusions:

  • The angiotensin II AT1 receptor subtype is implicated in cardiac hypertrophy.
  • The role of the AT2 receptor in cardiac function requires further investigation, potentially involving cell growth and proliferation.
  • Further research utilizing cloned receptors and selective antagonists is essential for a comprehensive understanding of Angiotensin II's role in cardiovascular disorders.